Caspofungin (Cancidas®) has not been endorsed for use in paediatric patients within NHS Wales for the treatment of invasive aspergillosis either unresponsive to amphotericin or itraconazole or in paediatric patients intolerant of amphotericin or itraconazole, invasive candidiasis and empirical treatment of systemic fungal infections in paediatric patients with neutropenia. The holder of the marketing authorisation is not in a position to progress a submission to AWMSG for the appraisal of caspofungin (Cancidas®) for the above indications. As a result, AWMSG cannot provide advice to the Minister for Health and Social Services.